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Abstract
Background: Clinical outcomes of novel coronavirus 2019 disease (COVID-19) in
onco-hematological patients are unknown. When compared to non-
immunocompromised patients, onco-hematological patients seem to have higher
mortality rates.
Aims: We describe the characteristics and outcomes of a consecutive cohort of
24 onco-hematological patients with COVID-19 during the first month of the pan-
demic. We also describe variations in healthcare resource utilization within our hema-
tology department.
Methods and Results: Data from patients between the first month of the pandemic
were retrospectively collected. Clinical and logistic data were also collected and com-
pared with the average values from the prior 3 months of activity. Prevalence of
COVID-19 in our hematological population was 0.4%. Baseline characteristics were
as follows: male sex: 83%, lymphoid diseases: 46%, median age: 69 (22-82) years.
Median follow-up in survivors was 14 (9-28) days and inpatient mortality rate was
46%. Average time to moderate/severe respiratory insufficiency and death were
3 (1-10) and 10 (3-18) days, respectively. Only 1 out of every 12 patients who devel-
oped moderate to severe respiratory insufficiency recovered. Upon univariate analy-
sis, the following factors were associated with higher mortality: age ≥ 70 years
(P = .01) and D-dimer ≥900 mcg/L (P = .04). With respect to indirect effects during
the COVID-19 pandemic, and when compared with the prior 3 months of activity,
inpatient mortality (excluding patients with COVID-19 included in the study)
increased by 56%. This was associated with a more frequent use of vasoactive drugs
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(+300%) and advanced respiratory support (+133%) in the hematology ward. In the
outpatient setting, there was a reduction in initial visits (−55%) and chemotherapy
sessions (−19%). A significant increase in phone visits was reported (+581%).
Conclusion: COVID-19 pandemic is associated with elevated mortality in hematologi-
cal patients. Negative indirect effects are also evident within this setting.
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1 | INTRODUCTION
The novel coronavirus SARS-CoV2 recently emerged as a global
threat.1 High hospitalization (around 20% of diagnosed cases) and
mortality rates (2%-3%) of patients with COVID-19 have led to an
unprecedented burden on healthcare systems.2,3 Indeed, the impact
of COVID-19 has even prevented healthcare professionals from con-
tinuing normal utilization practices of healthcare resources for all
other health matters unrelated to the pandemic. Evidence of such can
be seen in emergency departments and other vital services such as
onco-hematology departments.4,5 Recent reports from Chinese col-
leagues showed how symptomatic COVID-19 is perhaps associated
with higher mortality in the oncological population, with a range of
5% to 35%.6-8 In our study, we describe how this pandemic directly
affects our hematological patients. Furthermore, we analyze the indi-
rect effects of such pandemic on our hematology department in terms
of inpatient and outpatient activity of a population without
COVID-19 infection. With these data, we aim to further our under-
standing of the direct and indirect impacts of COVID-19 on onco-
hematological patients and departments to facilitate the conception
of effective contingency plans for future viral outbreaks.
2 | PATIENTS AND METHODS
2.1 | Data sources and statistics
The Institut Català d'Oncologia—Hospital Duran i Reynals (Barcelona,
Spain) is a tertiary oncology referral center for adult patients, with a
hospitalization ward of 26 beds dedicated to hematologic patients,
attending to a population of almost 1.5 million people. In the first part
of the study, we analyzed the direct effects of COVID-19 on a con-
secutive series of onco-hematological patients. We retrospectively
collected clinical data from patients between March 13, 2020 (the first
day of government-imposed restrictions related to COVID-19 in
Spain) and April 12, 2020. Data cut-off date was April 19, 2020. Data
were collected via a retrospective chart review. All patients were
≥18 years old and had an onco-hematological malignancy. COVID-19
diagnosis and response were confirmed in accordance with World
Health Organization criteria.9 Hematological disease type and status
were defined per international standard criteria.10,11 In the second
part of the study, we described the indirect effects of COVID-19 on
inpatient and outpatient activity in our department. Clinical and
logistic data from both types of activity were compared with average
values calculated from the prior 3 months (between December
13, 2019, and March 12, 2020).
The primary endpoint of the study was to describe the all-cause
in-hospital mortality rate in patients with hematologic neoplasms and
a confirmed diagnosis of COVID19 infection, defined as the propor-
tion of patients with COVID-19 who died to the overall cohort. Sec-
ondary endpoints included: description of patient characteristics,
average time from diagnosis to moderate/severe respiratory insuffi-
ciency (defined as requirement of oxygen support other than nasal
cannula, 3 L/m or pO2/FiO2 < 300 mmHg), and average time from
diagnosis to death. Descriptive data were reported as counts and per-
centages. The proportion of deaths was compared among baseline
characteristics using chi-squared test or Fisher's exact tests depending
on the number of events. The following variables were considered:
female vs male, age ≥ 70 years, ongoing chemotherapy (defined as
last chemotherapy within the last 30 days) vs follow-up, active disease
vs cured disease, 0-1 line of therapy vs ≥1, presence of comorbidities
(mostly cardiovascular risk factors and chronic heart, lung, and kidney
disease) vs no comorbidities, D-dimer ≥900 mcg/L (median of study
population) vs <900 mcg/L, radiological evidence of low tract respira-
tory infection in chest X-ray vs negative radiological findings. The
analysis was performed with STATA statistical software version
13.0.12
For patients without COVID-19, a description of healthcare
resource utilization between the first month of the COVID-19 pan-
demic and the average of the prior 3 months was provided. For the
inpatient setting, the following variables were analyzed: total number
of patients admitted, non-COVID-19 inpatient mortality rate, median
days of hospitalization, and the number of hematopoietic cell trans-
plants (HCT) performed (autologous and allogeneic). Also, we
described the number of patients without COVID-19 infection who
underwent sub-intensive care procedures in the hematology ward
(vasoactive drugs and high-flow nasal cannula), as well as the number
of patients who required intensive care unit (ICU) admission. For the
outpatient setting, the analysis was divided into the following clinical
units: HCT, acute leukemia and myelodysplastic syndromes, myelo-
proliferative diseases, lymphoid malignancies, multiple myeloma and
other monoclonal gammopathies, and interventional clinical trials. We
reported the following for each unit: the number of total visits, initial
visits, in-person follow-up visits, phone visits, and daily sessions of
chemotherapy/supportive therapy administered in the outpatient
clinic.
2 of 10 CONDOM ET AL.
2.2 | Structural reorganization due to COVID-19
Our institution is a tertiary oncology referral hospital for adult
patients, comprising four clinical departments (Medical Hematology,
Medical Oncology, Palliative Care, and Radiotherapy) and two services
(Radiology and Pharmacy). Each department has its own ward and
outpatient visitor area; however, outpatient therapy space is shared.
Furthermore, the hospital has its own infectious disease specialists,
and endocrinology and nutrition staff. For all other services, including
the intensive care unit, the hospital collaborates with Hospital
Universitari de Bellvitge (Barcelona, Spain). Due to the COVID-19
pandemic, our center and activities underwent structural reorganiza-
tion per regional, national, and international recommendations.13,14 At
the outpatient level, reduction of patient volume was sought with the
aim to minimize as best as possible the number of outpatient chemo-
therapies during the first 2 weeks of the pandemic. First, chemother-
apy sessions inside and outside the context of clinical trials were
initiated only if patients were considered as high risk for progression.
For myeloid malignancies and acute myeloid leukemia (AML), induc-
tion chemotherapies were continued and consolidation cycles were
performed in an inpatient setting to reduce the number of hospital
trips for the patient. For lymphoid malignancies, only severely symp-
tomatic patients or those at high risk of developing complications
started chemotherapy. Also, treatments were switched to an oral pre-
sentation whenever possible (eg, intramuscular methotrexate was
changed to oral methotrexate for acute lymphoblastic leukemia main-
tenance) and nonessential treatments were postponed (eg, bis-
phosphonate therapy and intravenous iron therapy). For transplant
and cell therapy, the following categories were considered high risk:
allogeneic HCT for acute myeloid leukemia, aplastic anemia, any
advanced stage of lymphoma not in complete remission, no further
option of another cycle of chemotherapy, patients included in clinical
trials, and chimeric antigen receptor cell candidates. New infusion
dates were proposed in order to have no more than one allogeneic
HCT per week. Cryopreservation of allogeneic products from related
and non-related donors was done prior to patient admission and con-
ditioning in accordance with local (Registro de Donantes de Médula
Ósea) and international (European Bone Marrow Transplantation
Society) recommendations.13-15 Nonessential visits were substituted
with phone visits whenever possible.
Palliative care and the emergency units of the hospital were
converted into COVID-19 wards. In order to prevent nosocomial
COVID19 outbreaks in a high-risk ward, nasopharyngeal swabs for
COVID19 were performed in all patients 24 to 48 hours before their
scheduled admission. Due to the restrictive triage protocol, no change
in room pressure was implemented. No family members were autho-
rized to stay with patients during their hospital stay. Additionally, phy-
sicians were separated into two different teams for each ward service
(HCT, myeloid disease, and lymphoid disease) to minimize the loss of
workforce due to a possible contagion. Outpatient staff was physically
confined to specific areas. Teleworking was encouraged for all activi-
ties not requiring physical presence at the hospital. Prior agreement
with the ICU to have a referral intensive care specialist in the
hematology ward was made. This strategy was implemented with the
objective to delay transfers of critical patients and assume more clini-
cally complex cases, defined as those patients who require vasoactive
drug support and/or present with rapid acute respiratory insufficiency
and need noninvasive ventilation with high-flow oxygen therapy.
Patients admitted to the onco-hematological ward had the same phar-
macological treatments available as those admitted to the ICU, includ-
ing tocilizumab and high-dose corticosteroids.
3 | RESULTS
3.1 | Cohort description of patients with
COVID-19
Taking into consideration patients followed-up in the last 2 years in
our hematology department (n = 6779), the expected prevalence of
COVID-19 in our oncological population was 0.4%. This figure is simi-
lar to that reported in the general population of the same geographic
area (0.5%).16 Of the 25 patients identified, one was excluded from
survival analysis due to a non-oncological disease (sickle cell disease).
Upon analysis, only one patient was still hospitalized. Details con-
cerning patient characteristics and baseline conditions, COVID-19 dis-
ease presentation, treatment, and outcomes can be found in Table 1.
Median age of patients was 69 years (22-82); the majority of patients
were male (83%); and lymphoid malignancies were the most common
hematological disease (46%). Only two patients were neutropenic
upon diagnosis. Median follow-up in survivors was 14 days (7-29).
Mortality rate was 46%, higher than in the general population
(10%).16 Eight of 24 patients (33%) required advanced respiratory sup-
port (more than nasal cannula 3 L/min). Average time from diagnosis
to moderate to severe respiratory insufficiency was 3 days (1-10).
Average time from diagnosis to death was 10 days (3-18). Upon uni-
variate analysis, the only factors with a significant effect on these out-
comes were age ≥ 70 years (P = .01), D-dimer ≥900 mcg/L (P = .04),
and female sex (P = .02). Of the 17 potential patients who developed
respiratory insufficiency, eight required advanced respiratory support.
One patient required endotracheal intubation and ICU admission; two
received non-invasive mechanical ventilation in the hematology ward
and emergency department, respectively. Five patients received high
flux nasal cannula in the ward.
3.2 | Indirect effects of COVID-19 on
hematological outpatient and inpatient activity
During the first month of pandemic restrictions, monthly inpatient
activity of non-COVID-19 patients was affected (Table 2). The total
number of admissions dropped by 35% and mortality rate of these
patients increased by 56% (Figure 1). We observed an increased num-
ber of intensive care procedures performed in the hematology ward
(use of vasoactive drugs +300%). Critically ill patients received on-site
sub-intensive care. Finally, the number of autologous and allogeneic
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TABLE 1 Clinical characteristics of patients and disease outcomes
Baseline characteristics N. of patients (n = 24)
Median age, years (range) 69 years (22–82)
Male sex, n (%) 20/24 (83%)
Presence of comorbidities, n (%) 17/24 (71%)

















Number of lines of treatment received, n (%)
0–1 15/24 (62.5%)
>1 9/24 (37.5%)
Active disease, n (%) 20/24 (83%)
On active treatment, n (%) 14/24 (58%)
COVID-19 characteristics upon admission
Fever, n (%) 21/24 (86%)
Oxygen support requirement, n (%) 2/24 (8%)
Laboratory findings, n (%)
Lymphopenia <1000 × 109/L 14/24 (58%)
Neutropenia <1000 × 109/L 2/24 (8%)
D-dimer >250 μg/L 20/24 (83%)
LDH > 220 (U/L) 15/22 (68%)
2 missing cases
CPR >10 mg/L 19/23 (83%)
1 missing case
Radiological findings in chest radiograph, n (%)
Normal 10/24 (42%)
Lobar infiltrate/consolidation 2/24 (8%)
Bilateral interstitial infiltrates/consolidations 12/24 (50%)
Treatment
COVID-19-targeted therapy, n (%)
None 2/24 (8%)
HCQ only 8/24 (33%)
HCQ + L/R 13/24 (54%)
HCQ + D/R 1/24 (4%)
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HCTs was reduced by 85% and 50%, respectively, when compared
with the average calculated of the prior 3 months. A total of five
HCTs were delayed (two autologous HCT for patients diagnosed with
non-Hodgkin lymphoma and systemic amyloidosis, and three alloge-
neic HCTs for patients diagnosed with AML, Hodgkin lymphoma, and
multiple myeloma). Concomitantly, a total of three aphereses (two
from unrelated donors and one from a related donor) was frozen dur-
ing the study period.
Outpatient activity was severely affected during the COVID-19
period. The total number of first visits dropped by 55% (Figure 2). In
addition, the number of in-person follow-up visits decreased by
70%. Interestingly, the number of follow-up phone visits increased
by 581%. The average outpatient clinic activity (daily sessions of
chemotherapy and supportive care) decreased by 19%. No changes
were observed in relation to oral therapy administration. These
changes were homogeneous in all subunits. In spite of 7 of 32 trials
TABLE 1 (Continued)
Baseline characteristics N. of patients (n = 24)
Inflammatory syndrome-targeted therapy, n (%)
None 17/24 (71%)
Tocilizumab only 4/24 (17%)
Tocilizumab + steroids 1/24 (4%)
Interferon B 2/24 (8%)
Maximum respiratory support, n (%), %a
None 9/24 (37.5%)
Nasal cannula 3/24 (12.5%)
Venturi mask 2/24 (8%)





Acute respiratory distress syndrome, n (%) 12/24 (50%)
Other documented concurrent infections, n (%)
Bacterial respiratory tract 3/24b (12%)
Bacterial, non-respiratory tract 2/24c (8%)
Non-bacterial infections 0/24 (0%)
Acute kidney injury AKIN III 2/24 (8%)
Stroke 1/24 (4%)
Skin rash 3/24 (12.5%)
Outcomes
Clinical outcomes, n (%)
Cured and discharged 12/24 (50%)
Death 11/24 (46%)
Still admitted 1/24 (2%)
Median time from diagnosis to respiratory deterioration (days, range) 3 (1–10) days
Median time from diagnosis to death (days, range) 10 (3–18) days
Median follow-up in survivors (days, range) 14 (9–28) days
Abbreviations: AITL, angioimmunoblastic T-cell lymphoma; AKIN, Acute Kidney Injury Network; AML, acute myeloid leukemia; ASCT, autologous stem cell
transplant; CLL, chronic lymphocytic leukemia; CMML, chronic myelomonocytic leukemia; CRP, C reactive protein; D/R, Darunavir/Ritonavir; DLBCL,
diffuse large B-cell lymphoma; EI, endotracheal intubation; FL, follicular lymphoma; HCQ, hydroxychloroquine; HCT, hematopoietic cell transplantation;
HFNC, high flow nasal cannula; HL, Hodgkin lymphoma; LDH, lactate dehydrogenase; LGL, large granular lymphocytes; L/R, Lopinavir/Ritonavir; MCL,
mantle cell lymphoma; MDS, myelodysplastic syndrome; MM, multiple myeloma; NIMV, noninvasive mechanical ventilation; SA, systemic amyloidosis;
tMZL, transformed marginal zone lymphoma.
aNasal cannula administers up to 3 L oxygen/min; Venturi mask: 3-15 L oxygen/min, at 25%-50% FiO2; Monaghan reservoir: 15 L oxygen/min, 100% FiO2.
bBacterial respiratory tract superinfections: 2 Haemophilus influenzae, 1 Branhamella catarrhalis.
cBacterial, non-respiratory tract infections: 1 Clostridium difficile colitis, 1 polymicrobial vulvar abscess (Klebsiella pneumoniae, Staphylococcus aureus).
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TABLE 2 Differences in healthcare resources utilization between the prior 3 months and the COVID-19 first month
Average of prior 3 months (SD) First COVID-19 month Variation (%)
Inpatient setting
General
• Total admissions (n) 81 (±5.5) 53 −35
• Total discharges (n) 80 (±3.0) 76 −5
• Inpatient mortality (%) 5.0 (±3.5) 7.9 +56
Days of hospitalization (median) 9.9 (±1.13) 8.5 −14
Sub-intensive/intensive care
• Patients using vasoactive drugs (n) 1 (±1.0) 4 +300
• Patients using high-flow nasal cannula (n) 3 (±2.6) 7 +133
• Patient candidates for ICU admission (%) 4% (±3%) 9% +130
• Patients admitted to ICU on candidates (%) 100% 40% −60
Mortality ICU (%) 40% (±35%) 100% +157
HCT procedures
• ASCT (n) 7 (±3.0) 1 −85
AlloHCT (n) 4 (±1.7) 2 −50
Outpatient setting
Global
Total visits (n) 1395 (±195.3) 1405 +1
Number of first visits (n) 86 (±23.7) 39 −55
Number of in-person follow-up visits (n) 1097 (±204.5) 328 −70
Number of phone visits (n) 152 (±46.8) 1038 +581
Chemotherapy sessions and supportive therapya (n) 988 (±115.1) 803 −19
HCT unit
Total visits (n) 129 (±24.5) 149 +16
Number of in-person first visits (n) 14 (±4.6) 8 −43
Number of in-person follow-up visits (n) 102 (±12.5) 32 −69
Number of phone visits (n) 13 (±7.6) 109 +761
Acute leukemias and myelodysplasias
Total visits (n) 200 (±66.0) 258 +29
Number of first visits (n) 11 (±4.6) 3 −73
Number of in-person follow-up visits (n) 155 (±63.2) 42 −73
Number of phone visits (n) 34 (±10.4) 213 +526
Chemotherapy sessions and supportive therapya (n) 601 (±51.6) 496 −17
Myeloproliferative diseases
Total visits (n) 74 (±37.4) 86 +15
Number of first visits (n) 6 (±4.1) 1 −84
Number of in-person follow-up visits (n) 68 (±37.6) 19 −72
Number of phone visits (n) 9 (±3.8) 66 +607
Chemotherapy sessions and supportive therapya (n) 0 0 —
Lymphoid malignanciesb
Total visits (n) 324 (±23.0) 322 −1
Number of in-person first visits (n) 29 (±3.2) 16 −44
Number of in-person follow-up visits (n) 278 (±25.1) 61 −78
Number of phone visits (n) 18 (±14.0) 245 +1261
Chemotherapy sessions and supportive therapya (n) 164 (±29.6) 147 −11
Multiple myeloma
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(with active enrollment) on hold during the first month of the
COVID-19 outbreak in Barcelona, the number of patients enrolled in
clinical interventional studies did not decrease significantly. A reduc-
tion of 20% in bone marrow biopsies and marrow aspirates was
reported. No COVID-19 infections were registered among
physicians.
4 | DISCUSSION
We report for the first time a descriptive analysis of the direct and
indirect effects of the COVID-19 pandemic on a tertiary oncology
referral center. Firstly, we performed an analysis of the characteris-
tics of symptomatic COVID-19 from a consecutive cohort of hema-
tological patients. The prevalence of symptomatic COVID-19 in our
patients' population was comparable to that of the general popula-
tion. This is different from what was previously reported in a Chi-
nese study, which suggested a higher risk of contagion in the
oncological population.8 The fact that patients diagnosed with
hematological disorders already adopt preventive isolation strate-
gies, such as social distancing, may have helped in keeping this prev-
alence stable. Most importantly, the mortality rate was higher than
that in the general population of the same geographical area and
time interval.16
TABLE 2 (Continued)
Average of prior 3 months (SD) First COVID-19 month Variation (%)
Total visits (n) 281 (±33.7) 230 −18
Number of first visits (n) 13 (±0.5) 3 −76
Number of in-person follow-up visits (n) 249 (±39.0) 11 −96
Number of phone visits (n) 19 (±5.8) 216 +1017
Chemotherapy sessions and supportive therapya (n) 223 (±33.8) 153 −31
Interventional clinical trials unit
Total visits (n) 377 (±22.8) 360 −5
Number of first visits (n) 13 (±6.6) 8 −40
Number of in-person follow-up visits (n) 246 (±26.9) 163 −34
Number of phone visits (n) 59 (±5.2) 189 +220
Number of enrolled patients (n) 11 (±5.8) 87 −25
Total number of BM aspirates/biopsies (n) 107 (±22) 86 −20
Abbreviations: alloHCT, allogeneic hematopoietic cell transplant; ASCT, autologous stem cell transplant; BM, bone marrow; CLL, chronic lymphocytic
leukemia; HL, Hodgkin disease; ICU, Intensive Care Unit; LPL, lymphoplasmacytic lymphoma; NHL, non-Hodgkin lymphoma; WD, Waldenström disease.
aOne chemotherapy session comprises a single day of administering chemo. (Azacitidine 1 cycle = 7 sessions; R-CHOP 1 cycle = 1 session). Transfusion
support was counted into this category only for acute leukemias and myelodysplastic syndromes only. Zolendronate infusion was counted into this
category for the multiple myeloma group.
bCLL, NHL, HD, WD, LPL.
F IGURE 1 Inpatient mortality
rate for patients without
COVID-19 infection during the
first pandemic month and the
prior 3 months
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Several factors could explain this difference. First of all, cancer is
generally a disease of the elderly. Older age was associated with
increased COVID-19-related mortality in almost all epidemiological
studies. Considering that the median age of our study population was
69 years, this could have likely contributed to poor survival.17 Addi-
tionally, the presence of comorbidities is another well-known risk fac-
tor.18 The majority of our patients had at least one chronic
cardiorespiratory disease. Indeed, cancer also represents a severe
comorbidity due to the disease itself, as well as the toxic effects of
oncological treatments. Other reports described a higher
COVID-19-related mortality in this population, ranging from 20% to
40%.6-8,19 In a recent large study, hematological malignancy was asso-
ciated with a higher risk of severe events in a COVID-19
population.19
The use of different types of therapy could also influence this
outcome. For example, B-cell depletion by use of rituximab could
potentially interfere with an adequate antibody response to the
SARS-CoV-2. The use of checkpoint inhibitors capable of eliciting an
increased immune response could have a role in favoring acute respi-
ratory distress syndrome within this setting. More data are needed to
clarify this hypothesis. In addition, being neutropenic could favor bac-
terial super-infections during COVID-19.
Nonetheless, such a high mortality rate appears superior to that
of any other common seasonal respiratory virus (eg, influenza viruses,
RSV), which usually does not exceed 10% to 20%, including in
severely immunocompromised patients.20,21 This may reflect the
higher virulence of SARS-CoV-2 as observed in the general
population.
We believe that the high mortality rate cannot be attributed
exclusively to the COVID19, especially considering that 20/24
patients (83%) had an active underlying hematological neoplasm.
However, in all patients who died, the leading cause of death was
respiratory insufficiency, which makes us believe that COVID-19 had
a critical role on the poor patients' outcomes.
Our study also confirms elevated age and D-dimer levels as risk
factors associated with higher mortality.17 Female sex was not
reported as a risk factor in other studies. However, these results were
obtained from a small cohort of patients and should be confirmed in
larger series. Apart from patient and virus-related risk factors, it is
possible that logistic factors could also play a role in COVID-19 mor-
tality. Even if this does not stand to be our case, patients requiring
ICU admission were prioritized according to ethical regional or
national guidelines. We can speculate that this prioritization might
have disadvantaged onco-hematological patients worldwide.
Finally, we suggest that onco-hematological patients could deteri-
orate faster than the general population. This is true in terms of time
from diagnosis to respiratory deterioration and death. A similar obser-
vation was reported elsewhere.8 Interestingly, we observed an inabil-
ity to recover from moderate to severe respiratory insufficiency. In
our series, 12 patients developed moderate to severe respiratory
insufficiency. Of those, only one recovered. On the contrary, almost
80% of patients with COVID-19-related respiratory insufficiency in
the general population will fully recover.22
Considering the indirect effects of COVID-19, it is important to
describe how such a pandemic was able to cause the collapse of a
modern healthcare system. Following national and international rec-
ommendations, we reduced our daily activity and reserved it only for
selected necessary cases. At an inpatient level, we observed an
increased mortality in our patients who did not present with
COVID-19 infection. This could probably be explained by the need to
attend to more palliative care patients in the hematology ward during
the COVID-19 period. To a lesser extent, a limited use of ICU and
F IGURE 2 Outpatient activity between the COVID-19 month and the average of the prior 3 months
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other essential hospital services could have played a role. Increased
COVID-19 mortality is in line with data from the national registry,
which reported a significant increase in death from all causes during
March 2020. As it concerns outpatient care, the number of first visits
decreased significantly in all units (see Table 2). The drop was espe-
cially significant in the myeloid division. It is possible that this effect
could be related to societal pressure to avoid hospital visits during this
period and to fear that infection may be more probable in such an
environment. Indeed, hospitals are considered high-risk spots for con-
tagion. We hypothesize that due to more unspecific symptoms, peo-
ple with myeloid malignancies might have avoided an early medical
consultation. Also, limited availability in radiology and surgical services
could have contributed to significant delays in new diagnoses of lym-
phomas. Epidemiological studies will be needed to confirm this
hypothesis and test another indirect effect of the COVID-19
pandemic.
Our ability to effectively reduce the number of in-person follow-
up visits was inversely related to a significant increase in phone visits
in our outpatient clinics. Telemedicine has shown to be a feasible
option within the onco-hematological setting. Apart from lowering the
probability of in-hospital contagion during a pandemic, telemedicine
should be implemented in the near future to minimize unnecessary
hospital trips and thereby improve patients' quality of life. Administer-
ing chemotherapy and supportive care was mildly reduced. This indi-
cates that chemotherapy is a medical procedure that can be delayed
but in exceptional cases only. Cancer remains a lethal disease; onco-
logical centers should guarantee the normal continuation of life-saving
procedures during an emergency situation.
In conclusion, COVID-19 resulted in higher mortality in our
cohort of hematological patients when compared to the general popu-
lation of the same geographical region. Patients and disease factors
could be involved in these poor outcomes; limited health resources
during an emergency situation could also have a role. Enrollment in
clinical trials should be encouraged in this setting.
Except for telemedicine and sub-intensive care interventions in
the ward, a significant reduction in almost all activities, including
first visits, in a hematology department has been observed. The cur-
rent indirect effects of the SAR-CoV-2 pandemic could potentially
lead to additional negative effects on the hematological population
(mostly in relation to decreased intensive care services for admitted
patients and decreased diagnoses in the outpatient setting). Larger
studies with a prolonged follow-up will be necessary to understand
in-depth clinical characteristics of this new infection and its indirect
effects. A more comprehensive view of how a pandemic could affect
a hematological center in the modern era could facilitate the con-
ception of improved contingency plans in the advent of health
emergencies.
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